BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 27538055)

  • 21. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
    Proctor AE; Thompson LA; O'Bryant CL
    Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: A systematic review and meta-analysis.
    Xie P; Lefrançois P
    J Am Acad Dermatol; 2018 Dec; 79(6):1089-1100.e17. PubMed ID: 30003981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of advanced basal cell carcinoma with sonidegib: perspective from the 30-month update of the BOLT trial.
    Chen L; Aria AB; Silapunt S; Lee HH; Migden MR
    Future Oncol; 2018 Mar; 14(6):515-525. PubMed ID: 29119833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sonidegib: First Global Approval.
    Burness CB
    Drugs; 2015 Sep; 75(13):1559-66. PubMed ID: 26323341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor sonidegib to manage adverse effects: A retrospective case series.
    Villani A; Costa C; Fabbrocini G; Ruggiero A; Scalvenzi M
    J Am Acad Dermatol; 2021 Apr; 84(4):e211-e212. PubMed ID: 33301802
    [No Abstract]   [Full Text] [Related]  

  • 26. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
    Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
    Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the hedgehog pathway to treat basal cell carcinoma.
    Geeraert P; Williams JS; Brownell I
    J Drugs Dermatol; 2013 May; 12(5):519-23. PubMed ID: 23652945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy.
    Buetti-Dinh A; Jensen R; Friedman R
    BMC Cancer; 2018 May; 18(1):569. PubMed ID: 29776351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study.
    Dummer R; Guminksi A; Gutzmer R; Lear JT; Lewis KD; Chang ALS; Combemale P; Dirix L; Kaatz M; Kudchadkar R; Loquai C; Plummer R; Schulze HJ; Stratigos AJ; Trefzer U; Squittieri N; Migden MR
    Br J Dermatol; 2020 Jun; 182(6):1369-1378. PubMed ID: 31545507
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma.
    Lacouture ME; Dréno B; Ascierto PA; Dummer R; Basset-Seguin N; Fife K; Ernst S; Licitra L; Neves RI; Peris K; Puig S; Sokolof J; Sekulic A; Hauschild A; Kunstfeld R
    Oncologist; 2016 Oct; 21(10):1218-1229. PubMed ID: 27511905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor.
    Skvara H; Kalthoff F; Meingassner JG; Wolff-Winiski B; Aschauer H; Kelleher JF; Wu X; Pan S; Mickel L; Schuster C; Stary G; Jalili A; David OJ; Emotte C; Antunes AM; Rose K; Decker J; Carlson I; Gardner H; Stuetz A; Bertolino AP; Stingl G; De Rie MA
    J Invest Dermatol; 2011 Aug; 131(8):1735-44. PubMed ID: 21430703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of sonidegib for the management of basal cell carcinoma: a drug safety evaluation.
    Villani A; Scalvenzi M; Micali G; Lacarrubba F; Genco L; Ruggiero A; Fornaro L; Guerrasio G; Potestio L
    Expert Opin Drug Saf; 2023; 22(7):525-531. PubMed ID: 37326221
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery and preclinical development of vismodegib.
    Gould SE; Low JA; Marsters JC; Robarge K; Rubin LL; de Sauvage FJ; Sutherlin DP; Wong H; Yauch RL
    Expert Opin Drug Discov; 2014 Aug; 9(8):969-84. PubMed ID: 24857041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study.
    Lear JT; Migden MR; Lewis KD; Chang ALS; Guminski A; Gutzmer R; Dirix L; Combemale P; Stratigos A; Plummer R; Castro H; Yi T; Mone M; Zhou J; Trefzer U; Kaatz M; Loquai C; Kudchadkar R; Sellami D; Dummer R
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):372-381. PubMed ID: 28846163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dynamic optical coherence tomography evaluation in locally advanced basal cell carcinoma during sonidegib treatment.
    Cantisani C; Musolff N; Longo C; Di Guardo A; Rovaldi E; Rossi G; Sasso F; Farnetani F; Rega F; Bánvölgyiv A; Azzella G; Paolino G; Pellacani G
    J Eur Acad Dermatol Venereol; 2024 May; 38(5):967-973. PubMed ID: 38270330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion.
    Dummer R; Ascierto PA; Basset-Seguin N; Dréno B; Garbe C; Gutzmer R; Hauschild A; Krattinger R; Lear JT; Malvehy J; Schadendorf D; Grob JJ
    J Eur Acad Dermatol Venereol; 2020 Sep; 34(9):1944-1956. PubMed ID: 31990414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.
    Rodon J; Tawbi HA; Thomas AL; Stoller RG; Turtschi CP; Baselga J; Sarantopoulos J; Mahalingam D; Shou Y; Moles MA; Yang L; Granvil C; Hurh E; Rose KL; Amakye DD; Dummer R; Mita AC
    Clin Cancer Res; 2014 Apr; 20(7):1900-9. PubMed ID: 24523439
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
    Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
    J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic treatments for basal cell carcinoma (BCC): the advent of dermato-oncology in BCC.
    Ali FR; Lear JT
    Br J Dermatol; 2013 Jul; 169(1):53-7. PubMed ID: 23488543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma.
    Sanmartín O; Llombart B; Carretero Hernández G; Flórez Menéndez Á; Botella-Estrada R; Herrera Ceballos E; Puig S
    Actas Dermosifiliogr (Engl Ed); 2021 Apr; 112(4):295-301. PubMed ID: 33197438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.